Cefdizime (cdz) is a drug product developed by Hoechst (Hester) in Germany. It is a third-generation cephalosporin. Compared with other similar drugs, this product not only has high-efficiency and broad-spectrum antibacterial activity, but also has immune enhancement effect. It is mainly used for pneumonia, bronchitis caused by sensitive bacteria such as chemical Book pneumococcus and Streptococcus Tonsillitis, pyelonephritis, cholangitis, urinary tract infection, gonococcal urethritis, pharyngitis, cholecystitis, gynecological infection and otitis media. Current research and application show that cefdizime also has high clinical value for children and the elderly with low immune ability.
This product has good antibacterial effect, and its lethality to Borrelia burgdorferi is significantly higher than that of ceftriaxone and minocycline. At the same time, Z can widely enhance the chemotaxis, phagocytosis and sterilization functions of phagocytes, enhance the oxidation reaction and respiratory burst related to phagocyte oxidation dependent sterilization system, and cooperate with non oxygen dependent sterilization system, so as to enhance the phagocytosis and sterilization of phagocytes.
Clinically, it can be applied to bacterial infection symptoms such as lower respiratory tract infection, meningitis, surgical infection, urogenital system infection, upper respiratory tract infection and ear infection.